Radiation and chemotherapy for high‐risk lower grade gliomas: Choosing between temozolomide and PCV

Cancer Medicine - Tập 9 Số 1 - Trang 3-11 - 2020
Susan G. R. McDuff1, Jörg Dietrich2, Katelyn M. Atkins3, Kevin Oh4, Jay S. Loeffler4, Helen A. Shih4
1Department of Radiation Oncology, Duke Cancer Center, Medicine Circle, Durham, NC, USA
2Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA
3Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
4Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA

Tóm tắt

AbstractPurpose

The majority of patients with high‐risk lower grade gliomas (LGG) are treated with single‐agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy. This article aims to evaluate the evidence and rationale for the widespread use of TMZ instead of PCV for high‐risk LGG.

Methods and Materials

We conducted a literature search utilizing PubMed for articles investigating the combination of radiotherapy and chemotherapy for high‐risk LGG and analyzed the results of these studies.

Results

For patients with IDH mutant 1p/19q codeleted LGG tumors, there is limited evidence to support the use of TMZ. In medically fit patients with codeleted disease, existing data demonstrate a large survival benefit for PCV as compared to adjuvant radiation therapy alone. For patients with non‐1p/19q codeleted LGG, early data from the CATNON study supports inclusion of adjuvant TMZ for 12 months. Subset analyses of the RTOG 9402 and EORTC 26951 do not demonstrate a survival benefit for adjuvant PCV for non‐1p/19q codeleted gliomas, however secondary analyses of RTOG 9802 and RTOG 9402 demonstrated survival benefit in any IDH mutant lower grade gliomas, regardless of 1p/19q codeletion status.

Conclusions

At present, we conclude that current evidence does not support the widespread use of TMZ over PCV for all patients with high‐risk LGG, and we instead recommend tailoring chemotherapy recommendation based on IDH status, favoring adjuvant PCV for patients with any IDH mutant tumors, both those that harbor 1p/19q codeletion and those non‐1p/19q codeleted. Given the critical role radiation plays in the treatment of LGG, radiation oncologists should be actively involved in discussions regarding chemotherapy choice in order to optimize treatment for their patients.

Từ khóa


Tài liệu tham khảo

10.1634/theoncologist.2013-0345

10.1007/s00401-016-1545-1

Taylor JW, 2013, Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management. | Harvard Catalyst Profiles | Harvard Catalyst, Oncology, 27, 504

10.1002/cncr.31039

10.1056/NEJMoa1500925

10.1200/JCO.2002.08.121

10.1093/annonc/mdl258

10.1007/s11910-015-0615-4

10.1200/JOP.2016.018622

10.1200/JCO.2012.43.2229

10.1200/JCO.2012.43.2674

Field KM, 2014, Evolving management of low grade glioma: no consensus amongst treating clinicians, J Clin Neurosci, 2016, 81

10.1016/j.critrevonc.2006.04.005

10.1007/s11060-017-2443-7

Institute NC.Radiation therapy with concomitant and adjuvant temozolomide versus radiation therapy with adjuvant PCV chemotherapy in patients with anaplastic glioma or low grade glioma.

10.1200/JCO.2011.35.8598

BellEH WonM FlemingJ et al.Comprehensive prognostic and predictive molecular subgroup analysis within the high‐risk treatment arms of NRG oncology/RTOG 9802: a phase III trial of RT versus RT + PCV in High‐risk low‐grade gliomas. ASTRO Annual Meeting.Chicago IL;2019.

10.1200/JCO.2005.04.6078

10.1200/JCO.2005.04.3414

10.1200/JCO.2013.49.3726

10.1093/neuonc/nou297

10.2174/092986708784567707

10.1002/1097-0142(19841101)54:9<2006::AID-CNCR2820540937>3.0.CO;2-F

10.3322/caac.21204

10.1007/BF02897227

10.1021/jm00180a022

10.1215/S1152851703000516

10.3747/co.25.3680

10.1016/S0959-8049(05)80198-4

10.1586/14737140.1.1.13

10.1054/bjoc.2000.1316

10.1002/cncr.11949

10.1023/B:NEON.0000040809.97943.c0

10.1002/cncr.25035

10.1093/neuonc/not036

10.1056/NEJMoa043330

10.1016/S1470-2045(09)70025-7

10.1016/S0140-6736(17)31442-3

van denBentM ErridgeS VogelbaumMA et al.Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion. In: American Society of Clinical Oncology.Chicago IL;2019.

10.1016/j.ijrobp.2014.11.012

10.1200/JCO.2009.23.6497

Wick W, 2016, Long‐term analysis of the NOA‐04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide, Neuro Oncol, 18, 1529

Chang S, 2017, Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of nrg oncology RTOG 9813, Neuro Oncol, 19, 252

10.1200/JCO.2009.27.1932

10.1016/S1470-2045(16)30313-8

10.1093/neuonc/nor040

10.1215/15228517-2006-005

Tabouret E, 2015, Relationships between dose intensity, toxicity, and outcome in patients with oligodendroglial tumors treated with the PCV regimen, Anticancer Res, 35, 2901

10.1016/S0140-6736(18)31791-4

10.1111/j.1468-1331.2010.03151.x

10.6004/jnccn.2017.0166

10.1016/j.canlet.2016.01.024

Thông tin
Thông tin xuất bản

Cancer Medicine

Tập 9 Số 1

3-11

Thông tin tác giả